• Aethlon Medical said its independent Data Safety Monitoring Board reviewed safety data from the second cohort of clinical trial AEMD-2022-06 and recommended advancing to the third and final cohort.
• The study is evaluating the safety, feasibility, and dose-finding of the Hemopurifier device in patients with solid tumors receiving pembrolizumab or nivolumab.
• In Cohort 2, participants received 2 Hemopurifier treatments over 1 week, and the company reported no serious adverse events or dose-limiting toxicities related to the device or treatment to date.
• Cohort 3 enrollment is open, with participants planned to receive 3 treatments over 1 week at 3 clinical sites in Australia.
• The company said the study is designed to enroll about 9 to 18 patients and that a final data set and clinical study report will be prepared in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603240801PR_NEWS_USPR_____LA17050) on March 24, 2026, and is solely responsible for the information contained therein.